Annovis Bio, Inc. 8-K

What Happened

• Annovis Bio, Inc. announced on April 9, 2026 that it entered an Underwriting Agreement with Canaccord Genuity LLC for an underwritten registered direct offering expected to close on or about April 10, 2026. The Offering consists of 5,263,156 shares of common stock and accompanying warrants to purchase 5,263,156 shares. The combined offering price is $1.90 per share plus accompanying warrant, for gross proceeds of approximately $10 million before expenses. The Offering is being made under the company’s effective Form S-3 shelf registration.

Key Details

• Shares offered: 5,263,156 common shares; Warrants: 5,263,156 (one warrant per share).
• Price and proceeds: $1.90 per share + warrant; expected gross proceeds ≈ $10 million.
• Warrant economics: exercisable beginning six months after issuance, expire 5.5 years after issuance, exercise price $2.50 per share.
• Underwriter and timing: Canaccord Genuity LLC; Underwriting Agreement dated April 9, 2026; expected closing on or about April 10, 2026, subject to customary closing conditions.

Why It Matters

• The offering provides immediate financing to support the continued clinical development of Annovis’s lead compound, Buntanetap, in a Phase 3 Alzheimer’s study, and for working capital and general corporate purposes, per the filing.
• Issuing new shares and detachable warrants is dilutive to existing shareholders now (shares issued) and potentially later (if warrants are exercised). Warrants only become exercisable after six months and would bring in additional capital only if the stock trades above the $2.50 exercise price.
• Investors should note the timing, the expected cash inflow (≈$10M), and the potential increase in outstanding shares when assessing near-term funding sufficiency and dilution.